Strides Arcolab receives USFDA approval for imiquimod

Strides Arcolab has received abbreviated new drug application (ANDA) approval from the US Food & Drug Administration (USFDA) for Imiquimod cream. According to IMS data, the US market for generic imiquimod cream is approximately $ 140 million. This is the first product approval from Beltapharm, Strides Arcolab’s USFDA approved semi-solids facility in Milan, Italy. The product will be marketed directly by Strides in the US market.
 
Imiquimod cream is a topical skin cream indicated for the treatment of certain types of actinic keratoses (precancerous skin lesions) on the face or scalp, and external genital and perianal warts in patients 12 years and older.